Post-partum haemorrhage: beyond the confrontation between misoprostol and oxytocin

The Lancet

Volumn 375, Issue 9710, 2010, Pages 176-178

  Buekens, Pierre ^a   Althabe, Fernando ^b  

^a TULANE UNIVERSITY   (United States)

^b INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; OXYTOCIN;

ARTICLE; CLINICAL TRIAL; DELIVERY; DRUG CHOICE; DRUG EFFICACY; HUMAN; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; UNSPECIFIED SIDE EFFECT;

EID: 73949098617     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60066-9     Document Type: Note

References (11)

1. Khan K.S., Wojdyla D., Say L., Gülmezoglu A.M., and Van Look P. WHO analysis of causes of maternal death: a systematic review. Lancet 367 (2006) 1066-1074
2. Blum J., Winikoff B., Raghavan S., et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet 375 (2010) 217-223
3. Winikoff B., Dabash R., Durocher J., et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet 375 (2010) 210-216
4. Department of Making Pregnancy Safer, WHO. WHO recommendations for the prevention of postpartum haemorrhage. http://www.who.int/making_pregnancy_safer/publications/WHORecommendationsforPPHaemorrhage.pdf (accessed Jan 3, 2010).
5. Prendiville W.J., Elbourne D., and McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev 3 (2000) CD000007.
6. Cotter A.M., Ness A., and Tolosa J.E. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 4 (2001) CD001808.
7. Derman R.J., Kodkany B.S., Goudar S.S., et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 368 (2006) 1248-1253
8. Gülmezoglu A.M., Villar J., Ngoc N.N., et al., for the WHO Collaborative Group to Evaluate Misoprostol in the Management of the Third Stage of Labour. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 358 (2001) 689-695
9. Tsu V.D., Sutanto A., Vaidya K., Coffey P., and Widjaya A. Oxytocin in prefilled Uniject injection devices for managing third-stage labor in Indonesia. Int J Gynaecol Obstet 83 (2003) 103-111
10. Althabe F., Buekens P., Bergel E., et al. A behavioral intervention to improve obstetrical care. N Engl J Med 358 (2008) 1929-1940
11. Hofmeyr G.J., Gülmezoglu A.M., Novikova N., Linder V., Ferreirab S., and Piaggioa G. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ 87 (2009) 666-677